Zai gains China rights to BMS's brivanib

Bristol-Myers Squibb Co.(NYSE:BMY) granted Zai Laboratory Inc. (Shanghai, China) exclusive rights in China, including Hong Kong and Macau, to oral brivanib to treat oncology indications including hepatocellular carcinoma (HCC). The compound is a dual inhibitor of VEGFR-2 and fibroblast growth factor (FGF) receptor 1 ( FGFR1; CD331)

BMS is eligible for milestones and royalties, has the option to co-promote brivanib with Zai in China, and retains all rights to brivanib outside China. Specific financial terms were not disclosed. ...